An estimated 47 million people worldwide are living with dementia, making it a leading cause of dependence and disability.^[@R1][@R2][@R3]^ Because of rapid aging of the population, the number of people living with dementia is projected to triple in the next 30 years, and the socioeconomic burden of dementia to increase accordingly. The projected burden of dementia could be alleviated if improvements in life conditions and health care over the last decades have decreased dementia risk. Indeed, recent studies in North America and Europe have reported a decline in the incidence of dementia over the last 40 years, with possible reductions of 10%--38% per decade, but estimates are inconsistent and often imprecise.^[@R4][@R5][@R8]^

Reliable assessment of time trends in the incidence of dementia calls for careful monitoring in the general population, in a consistent manner over a prolonged period of time. Population-based cohort studies have generally collected data on dementia incidence over decades, but few have been designed and powered to test for differences across calendar time. Consequently, individual studies lack the precision to quantify time trends in dementia incidence, leaving projections of the future burden of disease uncertain, with the range of reported reductions in time trends allowing for a variation of tens of millions new cases of dementia in the coming decades. Large heterogeneity, notably in the applied methodology of prior analysis of secular trends, further hinders comparison and reliable prediction across populations.^[@R6],[@R9]^ In a multinational collaboration, we aggregated data from available long-term population-based studies from Europe and the United States to study the trend in dementia incidence and establish whether similar changes were observed in men and women.

Methods {#s1}
=======

Data sources and study population: Alzheimer Cohorts Consortium (ACC) {#s1-1}
---------------------------------------------------------------------

The ACC is composed of 9 cohorts selected based on predetermined criteria. Specifically, the included cohorts had to be prospective, population-based, have in-person examinations, a span of at least 15 years of available follow-up, and include at least 2,000 participants at baseline. In addition, many cohorts have data on genotype and extensive phenotyping, particularly of cardiovascular factors and acquisition of brain MRI. The consortium includes the Age, Gene/Environment Susceptibility (AGES)--Reykjavik Study, the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), the Cognitive Function and Ageing Studies (CFAS), the Framingham Heart Study (FHS), the Gothenburg population studies, the Personnes Agées QUID (PAQUID) study, the Rotterdam Study (RS), and the Three-City Study (3C). More detailed information on the ACC has been published previously.^[@R10]^

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

All the participating ACC studies were approved by their respective institutional review committees, and all participants provided written informed consent.

Cohorts {#s1-3}
-------

The present study included 7 participating cohorts (data collection summaries are presented in [table 1](#T1){ref-type="table"}), and include a total of 49,202 (minimum age of 65 at entry) participants, of whom 4,253 had developed dementia to date. Cohort descriptions have been provided previously.^[@R8]^ Briefly, the AGES-Reykjavik Study is a sample drawn from the population-based Reykjavik Study cohort.^[@R11]^ The original source population in the Reykjavik Study included a random sample of men and women born between 1907 and 1935 and living in Reykjavik in 1967. Between 2002 and 2006, 5,764 survivors of the original cohort were reexamined for the AGES-Reykjavik study. The CFAS comprises 2 population-based studies among individuals aged 65 years and over living in the community, including those in institutions.^[@R5]^ The original 6-site study began in 1989 (MRC-CFAS; response 80%), however, interviewing began in 1991 for the 3 sites that were selected for the current comparison study. This comparison study, with independent sampling across 3 similar sites, was initiated 2 decades later, with baseline interviewing undertaken from 2008 to 2010 (CFAS II; response 56%). For this analysis, the baseline and 2-year follow-up data are included. The FHS began in 1948 with the recruitment of an original cohort of 5,209 men and women who were 28--62 years of age at entry.^[@R12]^ In 1971, a second generation of study participants, including 5,124 children and spouses of children of the original cohort, were enrolled.^[@R13]^ The Gothenburg population studies consist of 4 studies among individuals representative of the Swedish population.^[@R14],[@R15]^ These include Prospective Population Study of Women, a study that includes 1,462 women aged 38 to 60 who have been followed since 1968; the Gothenburg H70 Birth Cohort Studies, which studies several birth cohorts of 70-year-olds recruited from 1971 and onwards, of which a cohort of 70-year-olds enrolled in 2000 were included in this study; and the second H85 study, which started in 2009 with the enrolment of a birth cohort of 85-year-olds. The PAQUID cohort is a population-based study in the southwest of France among 3,777 individuals aged 65 years or older recruited in 1988.^[@R16]^ There have been 12 subsequent waves of data collection at 1, 3, 5, 8, 10, 13, 15, 17, 20, 22, 25, and 27 years after the baseline assessment. Due to changes in diagnoses over the first years of follow-up, for trends analysis, only data from the 8-year follow-up were included.^[@R17]^ The RS is a prospective population-based cohort study comprising 14,926 participants aged 45 years or older.^[@R18]^ Baseline data of 7,983 participants were collected between 1990 and 1993 (response 78%), with subsequent cohort expansions in 2000 (3,011 individuals, 67%) and 2006 (3,236 individuals, 65%). Participants are interviewed at home and reexamined at a dedicated research center once every 4 years. The entire cohort is continuously under surveillance for disease outcomes through linkage of electronic medical records with the study database. 3C is a longitudinal population-based study of the relation between vascular diseases and dementia in persons aged 65 years and older.^[@R19]^ Between 1999 and 2001, a total of 9,294 noninstitutionalized persons were recruited from the electoral rolls of 3 French cities: Bordeaux (southwest), Dijon (northeast), and Montpellier (southeast). Extensive follow-up examinations were performed at home or in a dedicated research center every 2 years after the baseline assessment, comprising standardized questionnaires, clinical examinations, and detailed cognitive assessment. An overview of the study populations is presented in [table 1](#T1){ref-type="table"}.

###### 

Demographics and characteristics of cohorts
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The ARIC study and the CHS, which are also part of the ACC, were not included in these analyses as ARIC did not have sufficient follow-up at the time of these analyses and the CHS had consistent data on long-term follow-up available in only a small subset of the (Pittsburgh) population only.

Assessment of dementia and Alzheimer disease (AD) {#s1-4}
-------------------------------------------------

Our primary outcome of interest is a diagnosis of all-cause dementia with a secondary outcome of clinical AD, where available. Dementia diagnostic criteria were consistent across the study period for each study, and are based on either DSM-III-R (CFAS, Gothenburg studies, PAQUID, and RS) or DSM-IV (AGES, FHS, and 3C). The National Institute of Neurologic and Communicative Disorders and Stroke--Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria^[@R20]^ for AD diagnosis was used in all cohorts except CFAS and the Gothenburg studies, which did not have data on AD diagnosis.

Statistical analysis {#s1-5}
--------------------

Poisson regression was used to calculate 5-year incidence rates (IRs) and 95% confidence intervals (CIs). All models were adjusted for age at time of entry and sex, and the log of follow-up time was used as an offset variable with IRs presented for the middle age of each 5-year age group (e.g., for 65 to 69.9 age group we used the middle age of 67.5). A single participant was able to contribute to multiple age groups as long as that person was free from dementia at the start of the age-group category. A robust sandwich estimator was used to calculate the 95% CI to control for the violation of the independence assumption.^[@R21]^ Models for all-cause dementia were stratified by age and sex. Due to limited data and follow-up among men, the Gothenburg studies included only women for these analyses. For comparison between men and women, results from the sex-specific IRs were analyzed across all cohorts using the meta-package (version 4.8-4) of the statistical software R, version 3.4.2 with heterogeneity across studies being assessed with an *I*^*2*^ statistic.

Cohorts with sufficient follow-up data to create at least 2 epochs were included in the trends analysis. Cohort-specific, nonoverlapping epochs were created in order to maximize the person-years available in each cohort, with 2 epochs in 3C, 3 epochs in PAQUID, RS, and the Gothenburg studies, and 4 epochs in FHS. Cox proportional hazard regression models were used to calculate the 5-year cumulative hazards per epoch, and hazard ratios (HRs) for all-cause dementia and AD for each epoch relative to the first. In CFAS, Bayesian full likelihood imputation models were used to adjust for study design of CFAS I.^[@R22]^ All models were adjusted for age at entry of the epoch and sex, with the exception of the sex-stratified models, which were adjusted solely for age. Participants were included in an epoch if they were free of dementia at the beginning of the epoch and censored at the end of 5 years, at their last visit, when lost to follow-up, or at date of death, whichever came first. Similar to the incidence analyses, participants contributed to multiple epochs if they were free of dementia at the beginning of the epoch and we utilized a robust sandwich estimator for the covariance structure to estimate the 95% confidence limits to account for nonindependence.^[@R21]^ To compare temporal trends across studies, we then calculated a HR per 10-year change in calendar time. This is interpreted as a change in 5-year hazard per decade advance in calendar time and was estimated using years from the median date of the referent first epoch to the median start date of each epoch, divided by 10 and treated as a continuous variable in the model. This assumes the time trend is constant across the 25-year study period. Trends were meta-analyzed across all cohorts, with heterogeneity across studies assessed with an *I*^*2*^ statistic using the meta-package (version 4.8-4) of the statistical software R, version 3.4.2. To rule out any dominant effect of the largest studies on the pooled estimate, we performed sensitivity analyses in which we excluded one by one the studies with the largest weight until a minimum of 3 studies.

To visualize the impact of changing incidence in dementia both globally and within Europe and the United States, we used data from the 2012 and 2015 World Alzheimer Reports to estimate how a decreasing trend in incidence would impact the expected number of new cases per year by 2040. We used the change in total cases/year between 2010 and 2015 and extrapolated that same change for each 5-year interval, taking into account the increasing population size and increasing longevity through to 2040, which resulted in similar projections as given in the 2012 report. We then estimated the effect of a continued decline in incidence on the total number of new dementia cases until 2040, assuming effect estimates for time trends from the present study.

All analyses were done separately by investigators responsible for each cohort. In order to ensure harmonization in analyses, each cohort received a detailed analysis plan, including statistical code in both SPSS (IBM Corp., Armonk, NY) and SAS (SAS Institute, Cary, NC).

Data availability {#s1-6}
-----------------

Framingham Study data are available through BioLINCC, where qualified researchers can apply for authorization to access ([biolincc.nhlbi.nih.gov/studies/framcohort/?q=Framingham](https://biolincc.nhlbi.nih.gov/studies/framcohort/?q=Framingham)). Data of European cohorts are available upon request, after approval by the relevant institutional review boards, in keeping with informed consent and the national and EU data protection regulations. Requests can be directed to the following contacts: for AGES, the Icelandic Heart Association (<AGES_data_request@hjarta.is>); for RS, data manager Frank J.A. van Rooij (<f.vanrooij@erasmusmc.nl>); for CFAS, the national coordinator of the CFAS Collaboration Data Archive, Linda Barnes (<leb22@medschl.cam.ac.uk>); for 3C, the principal investigator Dr. Christophe Tzourio (<E3C.CoordinatingCenter@gmail.com> or <christophe.tzourio@u-bordeaux.fr>); for PAQUID, the coordinating investigator Dr. Catherine Helmer (<catherine.helmer@u-bordeaux.fr>); and for the Gothenburg Studies, the principal investigator Dr. Ingmar Skoog (<Ingmar.Skoog@neuro.gu.se>).

Results {#s2}
=======

Cohort characteristics and demographics of participants in the analyses per cohort are presented in [table 1](#T1){ref-type="table"}. Data on nearly 50,000 participants with 2--27 years of follow-up are included in this study. All the cohorts comprise more women than men, with a mean relative frequency of 59%. Mean age at baseline of the first epoch was between 71 and 77 for all cohorts ([table 1](#T1){ref-type="table"}).

A total of 49,202 participants were included in the incidence analyses and followed for a total of 256,805 person-years. A total of 4,253 incident cases of dementia were recorded in the data analyzed for the included cohorts ([table 1](#T1){ref-type="table"}). Across all cohorts, IRs by age group were consistent ([table 2](#T2){ref-type="table"}). As expected, the incidence of dementia increased with age, from 1.6 to 8.6 per 1,000 person-years in the youngest age group (65--69 years), to between 42.2 and 97.0 per 1,000 person-years in the oldest age group (85--89 years). In general, the CFAS II cohort and the FHS had the lowest IRs and RS observed the highest ([figure 1](#F1){ref-type="fig"}). This pattern was similar for the sex-specific results. When results were combined across cohorts, we saw little difference in IRs by age group, or between men and women ([figure 2](#F2){ref-type="fig"}).

###### 

Incidence rates (per 1,000 persons) by cohort, age groups, and sex
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![Incidence rates of dementia, stratified by cohort and age group\
AGES--Reykjavik Study = Age, Gene/Environment Susceptibility--Reykjavik Study; CFAS = Cognitive Function and Ageing Studies; FHS = Framingham Heart Study; PAQUID = Personnes Agées QUID.](NEUROLOGY2019008235FF1){#F1}

![Incidence rates of dementia by age group, comparing men vs women](NEUROLOGY2019008235FF2){#F2}

We directly compared and analyzed the 5-year HRs per 10-year increment in calendar time between cohorts. This showed a consistent decrease in the 5-year cumulative hazard of all-cause dementia in all cohorts ([figure 3A](#F3){ref-type="fig"}; [table 3](#T3){ref-type="table"}). Across studies, we saw a 13% (95% CI 7%--19%) decrease in all-cause dementia per decade since 1998. Patterns were similar for clinical AD (decrease per decade: 16% \[8%--24%\]; [figure 3B](#F3){ref-type="fig"}). The decrease in 5-year cumulative hazard for all-cause dementia was larger in men than women, with a 24% decrease (14%--33%) in men vs an 8% decrease (0%--15%) in women, again with little heterogeneity across studies (*I*^*2*^ = 0% and 5%, respectively) ([figure 3, C and D](#F3){ref-type="fig"}). Results were broadly unaltered by stepwise analysis excluding the 3 studies with the largest weight, with HRs (95% CI) of 0.84 (0.78--0.92), 0.87 (0.77--0.97), and 0.82 (0.71--0.95), after exclusion of, respectively, CFAS; CFAS and RS; and CFAS, RS, and FHS.

![Trends in the incidence of dementia\
The forest plots represent the incidence trend for (A) all-cause dementia, (B) Alzheimer disease, (C) all-cause dementia in men, and (D) all-cause dementia in women, expressed as a hazard ratio (HR) per 10-year advance in calendar time. This HR was calculated to compare temporal trends across studies, and can be interpreted as a change in the 5-year hazard per decade advance in calendar time. 3C = Three-City Study; CFAS = Cognitive Function and Ageing Studies; CI = confidence interval; FHS = Framingham Heart Study; RS = Rotterdam Study.](NEUROLOGY2019008235FF3){#F3}
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Change in incidence per decade by study and sex
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Discussion {#s3}
==========

In this analysis of data from 7 large cohort studies representing populations from 6 different countries, we show that the age-stratified IRs of dementia are consistent across cohorts and notably similar between men and women. When examining changes in the IR over the past 25 years, we observe a decline of 13% per decade, again consistent across studies, but somewhat stronger for men compared to women. If we assume continuation of this trend in Europe and North America into the coming decades---although this was not the main objective of our study---it could imply that 15 million fewer people will develop dementia by 2040 in high-income countries, compared to widely quoted projections of the global burden of disease.^[@R23]^ If the same continuous incidence reduction could be achieved worldwide, this could lead to a reduction in the expected incidence of dementia of up to 60 million new cases of dementia by 2040 ([figure 4](#F4){ref-type="fig"}).

![Projected incidence of dementia in millions\
Projected yearly incidence of dementia on the basis of current rates (solid lines) and projected incidence of dementia assuming continuation of a decreasing trend (dashed lines). Current rates are based on estimates from the 2012 World Alzheimer Report, which at the time estimated that 682 million new cases would occur over the 2010 to 2050 period.](NEUROLOGY2019008235FF4){#F4}

Several of the cohorts within the ACC have previously published data on time trends in the incidence of dementia.^[@R4],[@R5],[@R7],[@R8]^ The incidence trends described here are an important step towards consensus, with substantially greater precision arising from using consistent analytical techniques across cohorts. In addition, our analyses suggest that these time trends in dementia incidence have occurred in both men and women. However, the effects of this decline in age-specific incidence will also depend on concurrent changes in life expectancy.^[@R24]^ Reductions in years spent with cognitive disability in the United Kingdom from 1991 to 2011,^[@R5]^ and reductions in years lived with dementia in the United States over the last 30 years,^[@R7]^ raise hope that preventive efforts involving lifestyle and health care interventions against dementia can offset at least part of the growing burden of dementia from global gains in life expectancy.

The study has strengths and limitations. This analysis has greater precision derived from combining several large, long-term population-based cohorts that have strived to limit person attrition from the studies over many years. We have described methodologic considerations for studying trends in the incidence of dementia previously.^[@R10]^ It is important to note that despite inevitable differences in population demographics, genetic and lifestyle make-up, and ascertainment methods for dementia, incidence trends displayed relatively little heterogeneity across studies. Further, concurrent increases in life expectancy and increased awareness of dementia in the population may have led to underestimation of a downward trend arising from increased diagnosis efficiency.

As a first limitation, despite extensive efforts to limit attrition, differential dropout may have occurred when linkage to health records was not available. However, attrition that is constant over time is unlikely to affect secular trends. Second, while the definition of dementia as a syndrome has remained relatively constant, the definition and understanding of what should be called AD have shifted substantially over the past decades. In the absence of pathologically confirmed diagnoses in most cohort studies, it remains uncertain what pathologic changes may underlie the observed trends. Third, calculating the effect of the observed trends on future dementia incidence relies on various assumptions that were beyond the scope of the current study to address entirely, and studies applying multistate modeling remain required for accurate projections in light of changing risk factor burden and mortality. Fourth, the application of consistent entry criteria helped guarantee valid assessment of incidence trends, but may have led to selection of a somewhat healthier population and consequently underestimation of absolute IRs. Finally, the choice to limit our analyses to population-based cohorts in order to get the most accurate measure of population incidence has led to a study population containing only those of European ancestry living in either the United States or Europe, with a generalizability of our findings to no more than 16% of the world\'s total population. These analyses should therefore be expanded to include (future) population studies with more diverse populations both within the United States and around the globe.

A main challenge in finding a cause of declining temporal trends in dementia is that there have been many concurrent changes over time in possible key risk factors, including lifestyle education and health interventions such as blood pressure control and antithrombotic medication. While none of these has been specifically intended to halt cognitive decline, decades of cardiovascular risk management have likely had substantial effects on brain health, supported by reduction of small-vessel disease on brain imaging in more recent years.^[@R8]^ The challenge remains to identify the critical causal factors among a variety of interventions influencing blood pressure, cholesterol, and inflammation that may have contributed to the decrease. Improved access and provision of education is another major change over the past century that could explain decreasing dementia IRs over time.^[@R25]^

Contrasting reports on the incidence of dementia have emerged recently from Japan,^[@R26]^ China,^[@R27]^ and Nigeria,^[@R28]^ showing stable or even increasing IRs. Similarly, in multiethnic populations in the United States, declines have been seen in some,^[@R29]^ but not all studies.^[@R30]^ Against the backdrop of the large expected increases in dementia burden, particularly in Asia and Africa,^[@R23]^ these observations temper the optimism for low to middle income countries, and render it all the more necessary to unravel the causes underlying the trends seen in this present study. Comparison with other geographic regions may well aid in pinpointing similar or discordant trends. Overall increased ethnic and geographic diversity within the ACC and the wider research community is therefore an important ongoing goal.

The development we see now in the epidemiology of dementia is somewhat reminiscent of the first report of a decline in mortality from coronary heart disease in 1964.^[@R31]^ If history has taught us anything in that respect, it is the need for prolonged, consistent surveillance of disease and associated factors to enable the future modeling of trends and the identification of causes.^[@R9],[@R31]^ Similar to heart disease,^[@R31]^ we should caution that the rise on a global scale of obesity,^[@R32]^ diabetes,^[@R33]^ and hypertension^[@R34]^ may reverse trends in dementia over the coming decades. As such, continued surveillance for dementia in the population-based studies within the ACC provides the framework for further investigation of potential causes of the declining time trend in dementia incidence.

The incidence of dementia in Europe and North America is very similar among men and women and has declined by 13% per decade over the past 3 decades. Identification of the underlying causes is vital to sustain and possibly enhance these trends in the face of changing risk factor profiles. It is essential to achieve equal reductions in areas of the world where projected increases in dementia burden are steep, and improvements in incidence thus far absent.
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